Video: Prevent Blindness in ROP

Practical guidance for retina specialists on monitoring and treatment of retinopathy of prematurity.

By: Darius M. Moshfeghi, MD, Diana V. Do, MD

Retinal Physician October 21, 2025

5 Key Takeaways

1

Monitoring infants with retinopathy of prematurity (ROP) is crucial to prevent blindness.
2

Aflibercept is an approved treatment for ROP, while bevacizumab is commonly used off-label.
3

Results from anti-VEGF treatments can be observed within 48 hours, showing disease regression.
4

Unlike laser treatments, anti-VEGF is not a permanent solution, requiring follow-up evaluations.
5

Regular follow-ups with fluorescein are essential until around 60 weeks to ensure proper care.

Darius M. Moshfeghi, MD

Specialties: Ophthalmology

Bio: Darius M. Moshfeghi, MD, is a physician author in retinal disease and surgery. In Retinal Physician, he coauthored an article on the prevalence and management of retinal detachment in high myopia, addressing surgical challenges associated with long eyes, posterior vitreous detachment induction, chromovitrectomy, chorioretinal atrophy, and myopia-related retinal sequelae.

Diana V. Do, MD

Retina Specialist

Specialties: Ophthalmology

Bio: Diana V. Do, MD, is a retina specialist and author for Retinal Physician. Her work focuses on ophthalmology and retinal disease, with interest in clinical trials, practice management, and emerging therapies for retinal conditions. In her Retinal Physician column, Dr. Do discusses developments in retina care, including clinical research collaboration, international clinical trial infrastructure, and investigational treatments for neovascular age-related macular degeneration and diabetic macular edema. She has also referenced her training connections with the Wilmer Eye Institute.

PentaVision

Retinal Physician

Video: Prevent Blindness in ROP

5 Key Takeaways

1

2

3

4

5

Recommendations